SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sun Pharma's Halol plant gets USFDA import alert
Sun Pharma is second Indian drugmaker to get import alert in less than two months SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Update On Halol Facility - Additional Details
In furtherance of our communication dated today, December 8, 2022 regarding USFDA Import Alert at Halol facility, we wish to share additional details on the same in the form of Q&A, as attached herewith.
Buy Sun Pharmaceuticals Industries; target of Rs 1300: Sharekhan
Sharekhan is bullish on Sun Pharmaceuticals Industries has recommended buy rating on the stock with a target price of Rs 1300 in its research report dated December 07, 2022. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Update On Halol Facility
As per letter attached SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 06, 2022 for Raksha Sudhir Valia SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39 3 ) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Sun Pharma to benefit from strong outlook for its specialty portfolio
Sun Pharma's global specialty business grew 27.5% year-on-year in Q2, driven by products as Ilumya, used to treat Psoriasis; Cequa, an ophthalmology product; and Winlevi, a dermatology product
BNP Paribas bullish on these Indian pharma stocks post Q2 earnings. Here are its top picks
BNP Paribas has retained Sun Pharma, Fortis Healthcare and Metropolis as its top pharma stocks picks